• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Suanfarma, at the Core of a Better Life.

    Annexon Biosciences to Present at 43rd J.P. Morgan Conference

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants for New Employees

    GLOBENEWSWIRE

    Annexon Presents ARCHER Data on ANX007 in Geographic Atrophy

    GLOBENEWSWIRE

    Annexon Inducement Grants to Employees Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Annexon Reports Q3 2024 Results & Key Milestones

    GLOBENEWSWIRE

    Annexon Biosciences to Present at Jefferies London Conference

    GLOBENEWSWIRE

    Annexon Presents Ph 2 Vision Preservation Data With ANX007 In Dry AMD

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon To Present Phase 2 ARCHER Data For ANX007 In Dry AMD

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants To New Employees

    GLOBENEWSWIRE

    Annexon To Present Phase 2 ARCHER Data

    GLOBENEWSWIRE

    Annexon Expands Leadership in Commercial, Medical Economics

    GLOBENEWSWIRE

    Annexon Biosciences to Participate in Upcoming September Investor Conferences

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon Reports Q2 2024 Results And Key Anticipated Milestones

    GLOBENEWSWIRE

    Annexon Updates On ARCHER II Program In Geographic Atrophy

    GLOBENEWSWIRE

    Annexon Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon To Present Phase 2 Data On ANX007 In Geographic Atrophy

    GLOBENEWSWIRE

    Annexon Presents Positive Phase 3 Results for ANX005 in Guillain-Barré Syndrome

    GLOBENEWSWIRE

    Annexon To Present ANX005 Phase 3 Data In Guillain-Barré Syndrome At PNS 2024

    GLOBENEWSWIRE

    Annexon Announces Pricing of $125 Million Underwritten Public Offering

    GLOBENEWSWIRE

    Annexon`s neurological disease drug succeeds in late-stage study

    REUTERS

    Annexon Announces Proposed Public Offering of Common Stock

    GLOBENEWSWIRE

    Annexon: Positive Phase 3 Results For ANX005 In Guillain-Barré Syndrome

    GLOBENEWSWIRE

    Annexon To Host GBS Phase 3 Data Conference Call, Webcast

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants To New Employees

    GLOBENEWSWIRE

    Annexon Reports Q1 2024 Results, Key Anticipated Milestones

    GLOBENEWSWIRE

    Annexon Biosciences to Present at the Bank of America Health Care Conference

    GLOBENEWSWIRE

    Annexon Vision Protection Data for ANX007 in Geographic Atrophy at ARVO

    GLOBENEWSWIRE

    Annexon: ARVO Data On ANX007 Neuroprotection In Geographic Atrophy

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants to New Employees Under Nasdaq Rule

    GLOBENEWSWIRE

    Annexon to Present at the 23rd Annual Needham Virtual Healthcare Conference

    GLOBENEWSWIRE

    Annexon Reports Fourth Quarter and Year-End 2023 Financial Results

    GLOBENEWSWIRE

    Annexon Reports Inducement Grant to New Employee Under Nasdaq

    GLOBENEWSWIRE

    Annexon Reports Inducement Grant to New Employee Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    J.P. Morgan Predicts up to 140% Rally for These 2 ‘Strong Buy’ Stocks

    YAHOO FINANCE

    Annexon to Host Virtual R&D Day on Guillain-Barr Syndrome

    GLOBENEWSWIRE

    Annexon Reports Inducement Grant to New Employee Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones

    GLOBENEWSWIRE

    Annexon Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    Annexon Reports Phase 1 Results for ANX1502

    GLOBENEWSWIRE

    Annexon Outlines Global Registrational Program for ANX007

    GLOBENEWSWIRE

    Annexon Announces Pricing of $125.0M Underwritten Public Offering of Stock

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants to New Employees Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon to Participate in the 6th Annual Evercore ISI HealthCONx Conference

    GLOBENEWSWIRE

    Annexon Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Annexon Biosciences to Participate in Jefferies London Healthcare Conference

    GLOBENEWSWIRE

    Annexon Receives PRIME Designation from the EMA for ANX007

    GLOBENEWSWIRE

    Annexon Reports Inducement Grants to New Employees Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon Announces Clinical and Regulatory Progress for ANX005 Program

    GLOBENEWSWIRE

    Annexon Biosciences to Participate in 2023 Cantor Global Healthcare Conference

    GLOBENEWSWIRE

    Annexon Reports Inducement Grant to Employee Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon Highlights Reports Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Annexon Reports Inducement Grant to New Employee Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Annexon finds more silver linings in failed eye disease trial

    FIERCE BIOTECH

    Annexon Presents ARCHER Trial Results at ASRS Highlighting Potential of ANX007

    GLOBENEWSWIRE

    Annexon Biosciences Appointed Jamie Dananberg as Chief Medical Officer

    GLOBENEWSWIRE

    Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS

    GLOBENEWSWIRE

    Annexon reports topline results from Phase II trial of GA therapy

    CLINICAL TRIALS ARENA

    Annexon eye disease med failed phase 2 goal—the CEO is thrilled

    FIERCE BIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.